In Q1'26, ISRG's Gross Margin stood at 66.1%, Operating Margin reached 30.9%, and Net Profit Margin was 29.6%, reflecting a slight uptick in profitability metrics from the prior quarter. Over the period from Q2'23 to Q1'26, Gross Margin exhibited relative stability around 66%, with minor fluctuations including a dip to 65.9% in Q1'24 and a peak of 68.3% in Q2'24, indicating consistent cost management in gross operations. Operating Margin showed an overall upward trend, rising from 26.4% in Q2'23 to 30.9% in Q1'26, driven by peaks of 30.4% in Q4'24 and Q2'25, though it experienced volatility with a low of 23.3% in Q4'23. Net Profit Margin displayed more variability, ranging from 23.8% in Q3'23 to a high of 31.4% in Q4'23, before stabilizing around 28% in recent quarters, underscoring improving net efficiency amid occasional boosts from one-time factors. The chart highlights ISRG's strengthening operating and net margins, suggesting enhanced profitability despite gross margin steadiness, which could signal effective expense controls in a competitive medical device sector.